Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs
Status:
Not yet recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
For a few years, there has been a keen interest of clinicians and patients for "lighter"
antiretroviral strategies based on two- or even single drug regimens rather than the
canonical triple therapy, both as initial and maintenance therapy, despite the possibility
that ongoing viral replication may occur in some patients under triple-therapy.
We will therefore propose such simplification strategy (DTG/3TC) while maintaining
triple-therapy (DTG/ABC/3TC) in a control group and will perform an in depth analysis of the
replication-competent reservoir in blood and in tissues as well as measurements of residual
viremia and immune chronic activation/inflammation.